

A high-level summary of the quarterly pan-Canadian Pharmaceutical Alliance (pCPA) activity & processes

PCPA ACTIVITY



Initiated **14 files**
(Q3 2023: 15 files)



Completed **18 files**
(Q3 2023: 14 files)




Closed **3 files**
(Q3 2023: 5 files)



Declined **1 file**
(Q3 2023: 1 file)


FILES UNDER CONSIDERATION



Insights

- CADTH issued 11 positive and 1 'Do Not Reimburse' recommendations in Q4 2023. 7 recommendations were non-oncology and 5 were oncology.
- The volume of files under consideration was steady throughout Q4, slightly higher than the volumes seen in Q3.
- The average days under consideration increased slightly in Q4, bringing the average for year 2023 to 177 days.
- pCPA initiated 4 non-oncology files and 3 oncology files in Q4, while also initiating 7 files that did not follow a specific CADTH recommendation.

FILES UNDER NEGOTIATION




Insights


- The volume of files under negotiation at pCPA was lower in Q4 compared to the rest of the year.
- The volume of oncology files under negotiation was slightly lower than non-oncology files throughout Q4.
- The average days under negotiation in Q4 2023 was 115 days, bringing the annual average for 2023 to 105 days.

PCPA CAPACITY

Volume of Processed Files



Long Term Files



Insights

- pCPA completed 18 negotiations (6 oncology, 7 non-oncology, and 5 "other") with LOIs in Q4 2023, closed 3 negotiations (2 oncology and 1 non-oncology) without LOIs, and declined to negotiate 1 oncology file.
- 2 of the files that closed, Rybrevant and Ferriprox, had a positive CADTH recommendation.
- The file that was not negotiated, Atriance, had a positive HTA recommendation. Note that the Atriance file was a clinician submission for a generic product.
- The number of files under consideration for more than 6 months increased over the quarter from 8 to 12. 1 file, Poteligeo, had been under negotiation for more than 1 year at the end of 2023.

